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Abstract 
A number of studies have evaluated two functional polymorphisms on p53 Arg72Pro and 
GSTP1 Ile105Val, in relation to esophageal cancer susceptibility. However, the results remain 
conflicting rather than conclusive. This meta-analysis on 2919 cases and 4074 controls for p53 
Arg72Pro  and  1885  cases  and  2194  controls  for  GSTP1  Ile105Val  from  13  published 
case-control studies showed that no significant general main effects for GSTP1 Ile105Val on 
esophageal cancer risk. However, we found that the p53 Arg72Pro was associated with an 
increased  risk  of  esophageal  cancer  ((Pro/Arg  +Pro/Pro)  versus  Arg/Arg:  OR=1.20, 
95%CI=1.06-1.36) without any between-study heterogeneity.  
In the stratified analysis by ethnicity, we found that the increased esophageal cancer risk 
associated with p53 Arg72Pro polymorphism was more evident in Asian group ((Pro/Arg 
+Pro/Pro) versus Arg/Arg: OR=1.35, 95%CI=1.14-1.60, P=0.09 for heterogeneity test), al-
though we still failed to find any significant association between GSTP1 Ile105Val polymor-
phism  and  esophageal  cancer  risk  in  different  ethnicity.  These  results  suggest  that  p53 
Arg72Pro polymorphism, but not GSTP1 Ile105Val, may contribute to esophageal cancer 
development, especially in Asian. Additional well-designed large studies were required for the 
validation of this association. 
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Introduction 
Esophageal cancer, the sixth most common cause 
of cancer-related death in the world, occurs with in-
creased  frequency  in  speciﬁc  regions.  [1]  Survival 
rates for esophageal cancer are poor; 75% of patients 
die within 1 year after diagnosis, and the 5-year sur-
vival rate is only 5–10% .[1] The development of eso-
phageal cancer is a multifactorial process associated 
with  a  variety  of  risk  factors.  Cumulative  evidence 
suggests that tobacco smoking, heavy alcohol drink-
ing, micronutrient deficiency, and dietary carcinogen 
exposure may cause the disease.[2-5] However, even 
in the at-risk population, only a portion of exposed 
individuals develop the cancer in their life span, in-Int. J. Med. Sci. 2010, 7 
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dicating  that  there  may  be  important  genetic  basis 
rendering such individuals susceptible to the disease. 
The tumor-suppressor gene p53 is important for 
cellular  growth  control  once  the  DNA  is  subject  to 
damage or mutation and arrests the cell cycle in the 
G1  phase  to  allow  DNA  repair  or  apoptosis.[6]  Its 
mutation  is  widely  detected  in  all  types  of  cancer, 
including esophageal cancer.[6,7] It is now clear that 
disruption  of  p53  pathway,  such  as  through  inacti-
vating p53 mutations, is associated with the formation 
and progression of malignancies. For example, it has 
been shown that >50% of human tumors have inacti-
vating p53 mutations.[8] 
Glutathione S-transferase P1 (GSTP1) is quanti-
tatively the most important GST isoform in normal 
esophageal epithelium.[9] GSTP1 expression, GSTP1 
mRNA levels, glutathione content and GST enzyme 
activities  are  all  reduced  in  BE  (Barrett  esophagus) 
compared with normal esophageal epithelium.[9-13] 
Because  accumulating  evidence  indicates  p53  and 
GSTP1 play central role in cancer formation and pro-
gression, one may reason that functional single nuc-
leotide polymorphisms in these genes might render 
the carrier susceptible to cancer, including esophageal 
cancer. 
It was reported that the p53 gene is polymorphic 
and  among  its  single  nucleotide  polymorphisms,  a 
G>C  change  at  codon  72  (rs1042522)  results  in 
Arg>Pro amino acid substitution.[14] Although both 
variants are morphologically wild-type, the Pro/Pro 
genotype  is  less  effective  in  suppressing  cellular 
transformation.[15] Several studies have reported that 
the p53 codon 72 polymorphism may be associated 
with tumor susceptibility to a variety of cancers re-
cently.[16-18]  The  GSTP1  gene  displays  a  polymor-
phism, an A>G change at codon 105, resulting in an 
Ile-to-Val  substitution  (rs1695),  which  alters  the  en-
zymatic  activity  of  the  protein.[18]  This  has  been 
suggested as a putative high-risk genotype in various 
cancers.[19] Therefore, it’s reasonable to hypothesize 
that  the  p53  Arg72Pro  and  GSTP1  Ile105Val  poly-
morphisms  may  functionally  related  to  the  risk  of 
esophageal cancer. 
A  number  of  molecular  epidemiology  studies 
have been conducted to examine the association be-
tween  p53  Arg72Pro,  GSTP1  Ile105Val  polymor-
phisms and esophageal cancer susceptibility [19-33], 
but the results remain inconsistent.  To estimate the 
overall risk of p53 Arg72Pro, GSTP1 Ile105Val asso-
ciated with esophageal cancer risk and to quantify the 
potential between-study heterogeneity, we conducted 
a meta-analysis on 13 published case-control studies 
with 2919 cases and 4074 controls for p53 Arg72Pro 
and 1885 cases and 2194 controls for GSTP1 Ile105Val. 
Materials and Methods 
Identification and Eligibility of Relevant Stu-
dies.  We  attempted  to  include  all  the  case-control 
studies published to date on the association between 
p53 Arg72Pro, GSTP1  Ile105Val  polymorphisms  and 
esophageal cancer risk. Eligible studies were identi-
fied by searching the electronic literature PubMed for 
relevant  reports  (last  search  update  February  2010, 
using the search terms “p53”, “polymorphisms” and 
“esophageal  cancer”;  “GSTP1”,  “polymorphisms” 
and  “esophageal  cancer”).  Additional  studies  were 
identified  by  hands-on  searches  from  references  of 
original studies or review articles on this topic. If stu-
dies had partly overlapped subjects, only the one with 
a larger and/or latest sample size was selected for the 
analysis.  
Data  Extraction.  Two  investigators  indepen-
dently extracted data and reached a consensus on all 
of  the  items.  Data  extracted  from  these  articles  in-
cluded  the  first  author’s  name,  year  of  publication, 
country of origin, ethnicity, number of cases and con-
trols, genotype frequencies for cases and controls.  
Meta-Analysis.  The  risk  of  esophageal  cancer 
associated with  p53 Arg72Pro, GSTP1 Ile105Val po-
lymorphisms were estimated for each study by odds 
ratio (OR) with 95% confidence intervals (95%CI). For 
all studies, we evaluated the risk of the variant geno-
types  (Pro/Pro,  Val/  Val),  compared  with  the 
wild-type genotype (Arg/Arg, Ile/ Ile). Then we cal-
culated  the  ORs  of  the  polymorphisms,  using  both 
dominant and recessive genetic models of the variant 
72Pro and 105Val alleles. In addition, we conducted 
stratification  analysis  by  ethnicity.  The  χ2-based  Q 
statistic test was used for the assessment of hetero-
geneity, and it was considered significant for P < 0.05. 
We  used  the  fixed-effects  model  and  the  ran-
dom-effects  model  based  on  the  Mantel-Haenszel 
method and the DerSimonian and Laird method, re-
spectively, to combine values from each of the studies. 
When the effects were assumed to be homogenous, 
the fixed-effects model was then used; otherwise, the 
random-effects model was more appropriate. We also 
computed the power of the selected studies by using 
the  DSTPLAN4.2  software,  in  order  to  assess  the 
probability  of  detecting  an  association  between 
RANTES polymorphisms and asthma at the 0.05 level 
of significance, assuming a genotypic risk of 2.0 and 
1.5. The Egger’s test and inverted funnel plots were 
utilized to provide diagnosis of publication bias (Li-
near  regression  analysis,  ref.[34]  All  analysis  was 
done by using the Statistical Analysis System software 
(v.9.1.3, SAS Institute, Cary, NC) and Review Manage 
(v.4.2). All the P values were two-sided. Int. J. Med. Sci. 2010, 7 
 
http://www.medsci.org 
302 
Results 
The  selected  study  characteristics  are  listed  in 
Table  1  and  Table  2.  All  studies  indicated  that  the 
distributions of two polymorphism’s genotypes in the 
controls were both consistent with Hardy-Weinberg 
equilibrium  except  for  one  study  [26]for  p53 
Arg72Pro, and one studies [21] for GSTP1 Ile105Val. 
Considering  the  representation  of  samples,  which 
may directly result in untruthful effect, we excluded 
these  studies  [21,26]  with  a  departure  from  Har-
dy-Weinberg equilibrium from our analysis. As a re-
sult, 6 case-control studies (2919 cases and 4074 con-
trols) for p53 Arg72Pro and 9 studies (1885 cases and 
2194 controls) for GSTP1 Ile105Val were available for 
this  meta-analysis.  The  minor  Pro  allele  (for  p53 
Arg72Pro)  and  Val allele  (for GSTP1 Ile105Val) fre-
quency (MAF) were 0.44 and 0.20 for Asian studies, 
while  around  0.60  and  0.32  for  Mix  and  Caucasus 
populations, respectively. 
Table 1. Characteristics of published studies on p53Arg72Pro included in the meta-analysis 
Author (ref*)  Year  Origin  Ethnicity  SNP 
site 
Sample size 
(case/control) 
HWE MAF  
in controls 
Genotypic ORs&  Power (%) † 
homozygotes/ 
heterozygotes 
OR>1.5  OR>2.0 
Lee JM[22]  2000  China(Taiwan)  Asian  p53 Arg72Pro  90/254  0.427  0.40   2.56/1.86  37.5  80.2 
Vos M[23]  2003  South Afican  African  p53 Arg73Pro  73/115  0.216  0.41   0.44/0.96  27.0  63.5 
Hong Y[24]  2005  China  Asian  p53 Arg74Pro  758/1420  0.105  0.44   1.77/0.99  99.4  100.0 
Cai L[25]  2006  China  Asian  p53 Arg75Pro  204/389  0.107  0.47   2.25/1.43  64.8  97.7 
Yang W[26]  2008  China  Asian  p53 Arg76Pro  435/550  0.000  0.32   0.39/0.07  86.0  100.0 
Liu G[27]  2009  United States  Caucasian p53 Arg77Pro  302/453  0.066  0.26   1.05/01.18  70.6  99.2 
Canova C[19]  2009  European  Caucasian p53 Arg78Pro  1492/1443  0.660  0.73   1.00/0.95  99.6  100.0 
* The ref was referred to the reference numbers in this study. 
& data from the same source, so selected by the latest sample size. 
# NA: Not available. 
& Genotypic odds ratios for homozygotes and heterozygotes. 
† Power was calculated by the DSTPLAN4.2 software with MAF in controls as the frequency of risk factor, OR was selected 1.5 and 2.0 as the 
relative risk and а=0.05 as the significance. 
Table 2. Characteristics of published studies on GSTP1I le105Val included in the meta-analysis 
Author (ref*)  Year  Origin  Ethnicity  SNP 
site 
Sample size 
(case/control) 
HWE MAF  
in controls 
Genotypic ORs&  Power (%) † 
homozygotes/ 
heterozygotes 
OR>1.5  OR>2.0 
Lin DX&[28]  1998  China  Asian  GSTP1 
Ile105Val 
42/36  0.359  0.24   0.25/0.83  12.3  28.9 
Morita S[29]  1998  Japan  Asian  GSTP1 
Ile106Val 
66/164  0.412  0.16   0.26/0.19  19.2  49.2 
van Lieshout EM[30] 1999  The Netherlands Caucasian  GSTP1 
Ile107Val 
34/247  0.739  0.23   3.65/3.44  16.4  40.7 
Tan W&[31]  2000  China  Asian  GSTP1 
Ile108Val 
150/150  0.616  0.22   1.47/0.89  33.5  77.1 
Lee JM[22]  2000  China(Taiwan)  Asian  GSTP1 
Ile109Val 
90/254  NA#  NA#  NA#/ NA#  NA#  NA# 
Casson AG[21]  2003  Canada  Caucasian  GSTP1 
Ile110Val 
45/45  0.019  0.29   0.78/2.51  14.6  35.1 
Roth MJ[32]  2004  China  Asian  GSTP1 
Ile111Val 
131/454  0.057  0.22   0.79/0.88  43.0  88.2 
Casson AG[20]  2006  Canada  Caucasian  GSTP1 
Ile112Val 
56/95  0.834  0.35   2.22/1.36  21.7  52.7 
Cai L[25]  2006  China  Asian  GSTP1 
Ile113Val 
204/393  0.872  0.18   0.46/0.93  48.4  92.6 
Murphy SJ[33]  2007  Irish  Caucasian  GSTP1 
Ile114Val 
207/223  0.201  0.36   0.99/0.93  54.0  94.4 
Canova C[19]  2009  European  Caucasian  GSTP1 
Ile115Val 
1471/1405  0.330  0.32   0.97/1.13  99.9  100.0 
* The ref was referred to the reference numbers in this study. 
& data from the same source, so selected by the latest sample size. 
# NA: Not available. 
&Genotypic odds ratios for homozygotes and heterozygotes. 
† Power was calculated by the DSTPLAN4.2 software with MAF in controls as the frequency of risk factor, OR was selected 1.5 and 2.0 as the 
relative risk and а=0.05 as the significance. Int. J. Med. Sci. 2010, 7 
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As  shown  in  Table  3,  the  variant  homozygote 
(Pro/Pro)  for  p53  Arg72Pro  was  associated  with  a 
significantly  increased  risk  of  esophageal  cancer 
(Pro/Pro versus Arg/Arg: OR=1.43, 95%CI=1.23-1.68; 
P  =  0.10  for  heterogeneity  test)  compared  with 
wild-type  homozygote  (Arg/Arg).  We  also  found 
significant main effects in the dominant genetic model 
((Pro/Arg  +Pro/Pro)  versus  Arg/Arg:  OR=1.20, 
95%CI=1.06-1.36; P = 0.08 for heterogeneity test; Table 
3 and Figure 1). However, we failed to find any sig-
nificant main effects for GSTP1 Ile105Val on esopha-
geal  cancer  risk  in  different  genetic  models  tested 
(Table 3 and Figure 2).  
We  further  performed  stratified  analysis  ac-
cording to ethnicity (Asian and Mixed/ Caucasian 
group). As shown in the Table 4, we found that the 
increased esophageal cancer risk associated with p53 
Arg72Pro polymorphism was more evident in Asian 
((Pro/Arg  +Pro/Pro)  versus  Arg/Arg:  OR=1.35, 
95%CI=1.14-1.60, P=0.09 for heterogeneity test). Un-
fortunately, we still failed to find any significant as-
sociation  between  GSTP1  Ile105Val  polymorphism 
and esophageal cancer risk in different ethnicity. 
We used Funnel plot and Egger’s test to access 
the publication bias of literatures. As shown in Fig. 3 
A, the shape of the funnel plots seemed nonsymme-
trical  in  the  dominant  genetic  model  for  the  p53 
Arg72Pro, suggesting that there was significant pub-
lication bias. Egger’s test was used to provide statis-
tical evidence. As a result, the publication bias was 
observed slightly for p53 Arg72Pro (t=4.55, P = 0.01) 
but was disappeared (t=1.35, P = 0.25) when we ex-
cluded  the  study  [26]  departure  from  Har-
dy-Weinberg  equilibrium.  No  publication  bias  was 
observed for GSTP1 Ile105Val (t=1.13, P = 0.29), we 
also  excluded  the  study  [21]  departure  from  Har-
dy-Weinberg equilibrium and still did not found any 
publication bias for 28C/G (t=0.90, p=0.39).  
 
Table 3. Summary ORs of p53 and GSTP1 polymorphisms and esophageal cancer risk 
Comparison  No. of Cases  No. of Controls  OR  95%CI  P* 
p53 Arg75Pro     
Pro/Arg vs Arg/Arg  1761  2850  1.09   0.95-1.24  0.25  
Pro/Pro vs Arg/Arg  1720  2263  1.43   1.23-1.68  0.06  
Pro/Pro vs (Arg/Arg+Pro/Arg)  2919  4074  1.31   0.95-1.80  0.00  
(Pro/Arg +Pro/Pro) vs Arg/Arg  2919  4074  1.20   1.06-1.36  0.08  
GSTP1 Ile106Val   
Ile/Val vs Ile/Ile  1687  1917  0.99   0.74-1.32  0.00  
Val/Val vs Ile/Ile  1063  1295  1.00   0,81-1.23  0.28  
Val/Val vs (Ile/Ile+Ile/Val)  1885  2194  0.95   0.79-1.17  0.57  
(Ile/Val+Val/Val) vs Ile/Ile  1885  2194  0.95   0.73-1.25  0.00  
* Test for heterogeneity. Fixed-effects model was used when P value for heterogeneity test > 0.05; otherwise, random-effects model was used. 
 
Table 4. Association between esophageal cancer risk and the p53, GSTP1 polymorphisms, stratified by ethnicity. 
SNP site  Studies of  
available& 
No. of  
Cases 
No. of  
Controls 
OR#  95%CI  P* 
p53 Arg72Pro             
Asian  [22,24,25]  1052  2063  1.35  1.14-1.60  0.09 
Mix  [19,23,27]  1868  2011  1.04  0.86-1.25  0.60  
GSTP1 Ile105Val             
Asian  [22,25,29,31,32]  641  1415  0.99  0.66-1.49  0.00  
Caucasian  [19,20,30,33]    1768  1970  1.06  0.86-1.31  0.02  
# The OR was obtained in dominant genetic model. 
* Test for heterogeneity. Fixed-effects model was used when P value for heterogeneity test > 0.05; otherwise, random-effects model was used. 
& Studies of available was referred to the reference resource of the stratified variable, which data was available. 
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Figure 1. ORs (log scale) of esophageal cancer associated with p53 Arg75Pro for the Pro/Arg+Pro/Pro genotypes, compared 
with the Arg/Arg genotype. 
 
Figure 2. ORs (log scale) of esophageal cancer associated with GSTP1 Ile106Val for the Ile/Val+Val/Val genotypes, compared 
with the Ile/Ile genotype. Int. J. Med. Sci. 2010, 7 
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Figure 3. Funnel plot analysis to detect publication bias in esophageal cancer. Each point represents a separate study for the 
indicated association. For each study, the OR is plotted on a logarithmic scale against the precision (the reciprocal of the SE). 
 
Discussion 
The  GSTP1  gene,  which  encodes  the  GST  π 
isoenzyme,  is  the  most  important  form  in  the  eso-
phagus.[35] It can eliminate DNA oxidative products 
of thymidine or uracil propenal.[36] The 105Val form 
shows altered affinity and enzymatic activity for some 
substrates.[37-39]  However,  our  analysis  results 
showed  there  was  no  significant  relations  between 
GSTP1 Ile105Val polymorphism and esophageal can-
cer, but this conclusion was consistent with Hiyama T 
et  al’  s  review.[40]  These  findings  suggest  that  the 
GSTP1 Ile105Val genotype alone does not show any 
association with the susceptibility to esophageal can-
cer, even when stratified by subgroup. This finding is 
perhaps  not  surprising,  because  the  functional  evi-
dence to support the role of GSTP1 Ile105Val as an 
esophageal cancer risk factor is not strong. Although 
GSTP1 may encode the GST π isoenzyme in the eso-
phagus,  positive  effect  for  esophageal  cancer  fre-
quently  has  been  detected  in  those  who  had  some 
environment exposures such as smoke cigarettes, al-
cohol drinkers or low level of dietary selenium intake. 
Therefore,  it  is  reasonable  to  hypothesize  that  the 
GSTP1  Ile105Val  polymorphism  may  be  at  best  a 
modifier  for  esophageal  cancer  by  interactive  with 
some lifestyle and dietary habits, but is not a signifi-
cant independent susceptibility factor.  
The  p53  tumor  suppressor  pathway  is 
well-known to be crucial in maintaining genomic in-
tegrity  and  preventing  cells  from  oncogenic  trans-
formation. When a cell is exposed to genotoxic stress 
such as DNA damage and oncogene activation, the 
p53  protein  accumulates  rapidly  through  posttran-
scriptional  mechanisms  and  is  also  activated  as  a 
transcriptional factor, which leads to cell cycle arrest 
for DNA repair or apoptotic cell death [41]. Both mice 
and humans harboring germ line inactivating muta-
tions in one p53 allele are highly susceptible to cancer: 
they develop cancer very early in life and at very high 
frequencies. [42,43] 
The functional impact of this p53 polymorphism 
has been reported and the Arg/Arg genotype seems 
to induce apoptosis with faster kinetics and to sup-
press  transformation  more  efficiently  than  the 
Pro/Pro genotype.[15] It was shown that p53 Pro/Pro 
exhibits a lower ability to induce apoptosis in vitro 
than  p53Arg/Arg.[15]  In  a  pilot  study,  Zhang  et 
al.[44]  showed  that  subjects  carrying  the  p53 
72Pro/Pro genotype had a >2-fold increased risk for 
developing esophageal cancer. These results are con-
sistent with our present meta-analysis study. Thus, it 
is reasonable to hypothesize that the Arg72Pro poly-
morphism  with  reduced  activity  of  p53  may  play 
more important role in esophageal cancer risk. 
In the present meta-analysis on the association 
between  p53  Arg72Pro,  GSTP1  Ile105Val  polymor-
phisms and risk of esophageal cancer, we found that 
variant 72Pro  of  alleles p53  Arg72Pro  could  signifi-
cantly increase the risk of esophageal cancer, although 
the association were not significantly evident in most 
studies individually. However, we failed to find any 
significant association between GSTP1 Ile105Val and 
esophageal cancer risk. In stratified analysis, we fur-Int. J. Med. Sci. 2010, 7 
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ther  observed  that  the  association  between  p53 
Arg72Pro and risk of esophageal cancer was remained 
significant in Asian population. The different effect of 
p53 Arg72Pro polymorphism between ethnicity may 
result  from  different  genetic  background  and  envi-
ronmental  exposures,  which  may  contribute  to  the 
frequency of ethnic difference.  
It  is  worth  emphasizing  that  several  environ-
ment exposures are regarded as risk factors of  eso-
phageal cancer, especially tobacco smoking, which is 
an established etiologic factor for esophageal cancer 
[3,45], and exposure to smoke causes genotoxic stress 
including DNA damage or avoids potential saturation 
of enzyme activity.[46,47] Several data provided some 
support for one hypothesis that there may be existed 
significant  interaction  between  p53  Arg72Pro  or 
GSTP1 Ile105Val polymorphism and smoking, though 
there  were  not  enough  report  support  us  to  make 
meta-analysis  in  current  research.  Studies  with  a 
larger  sample  size,  especially  including  smoking  or 
another environment factors will be helpful to con-
firm the findings. 
Although  there  have  been  consistent  ﬁndings 
that  the  p53  codon  72  Pro/Pro  genotype  was  asso-
ciated with increased esophageal SCC risk [40], it is 
worth  mentioning  that  there  are  2  main  forms  of 
esophageal cancer histologically, squamous cell car-
cinoma (SCC) and adenocarcinoma, and each has dis-
tinct etiologic and pathologic characteristics. Squam-
ous cell is cancer located in epithelial cell of the mouth 
throat or lungs and adenocarcinoma is composed of 
cells  of  glandular  tissue.  Over  the  past  5  decades, 
many changes in the prevalence of esophageal cancer 
have  occurred.  Prior  to  this,  SCC  comprised  more 
than  95%  of  esophageal  malignancies  [48].  In  our 
meta-analysis, we had wanted to analysis the associa-
tion between these two gene polymorphisms and risk 
of  esophageal  cancer  according  to  the  different  pa-
thological  type,  but  most  of  the  included  research 
were majored on SCC, so we failed to conduct related 
stratified  analysis.  More  molecular  epidemiological 
studies on adenocarcinoma are needed to further elu-
cidate  the  real  association  of  the p53 Arg72Pro and 
GSTP1 Ile105Val polymorphism with esophageal car-
cinogenesis. 
In  conclusion,  this  meta-analysis  of  13 
case-control  studies  provided  evidence  that  the  p53 
Arg72Pro  polymorphism,  but  not  the  GSTP1 
Ile105Val, was significantly associated with increased 
risk of esophageal cancer, especially in Asian. Further 
well-designed large studies, particularly referring to 
gene-gene  and  gene-environment  interactions  are 
warranted  to  confirm  the  real  contribution  of  these 
polymorphisms to esophageal cancer susceptibility.  
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